{
    "hands_on_practices": [
        {
            "introduction": "The principle of en bloc resection for retroperitoneal sarcomas often necessitates the removal of adjacent organs to achieve negative margins. This exercise focuses on a common scenario: the planned sacrifice of a kidney. Before committing to a nephrectomy, it is the surgeon's responsibility to quantitatively predict the impact on the patient's overall renal function. This practice will guide you through the calculation of expected postoperative estimated Glomerular Filtration Rate ($eGFR$), integrating concepts of baseline function, contralateral compensation, and the effects of patient comorbidities, which is a critical skill for preoperative counseling and risk stratification .",
            "id": "5180202",
            "problem": "A patient with a large retroperitoneal sarcoma encasing the right renal hilum is planned for en bloc resection including right nephrectomy as part of definitive oncologic management. Preoperative functional assessment includes an estimated Glomerular Filtration Rate (eGFR) normalized to body surface area and a differential renal scintigraphy quantifying the fractional contribution of each kidney to total filtration under current conditions. Use the following scientifically grounded premises as the fundamental base: total glomerular filtration is the sum of contributions from each kidney, removal of one kidney eliminates its contribution, and surviving kidney function can adapt by physiologic hyperfiltration (compensation) that is classically modeled as a multiplicative increase over its baseline contribution, attenuated by comorbid factors that limit adaptive capacity.\n\nData:\n- Baseline estimated Glomerular Filtration Rate (eGFR) is $E_{0} = 84 \\,\\mathrm{mL/min/1.73\\,m^2}$.\n- The differential study indicates the right kidney contributes a fraction $f_{R} = 0.40$ of the baseline eGFR, and the left kidney contributes $f_{L} = 0.60$ of the baseline eGFR.\n- In the absence of limiting comorbidity, the contralateral kidney is expected to increase its filtration by a fractional compensation $c_{\\mathrm{norm}} = 0.30$ over its baseline contribution by $12$ weeks after unilateral nephrectomy.\n- The patient has diabetes mellitus and chronic vascular changes that attenuate compensation by a fractional attenuation $a = 0.25$, applied multiplicatively to $c_{\\mathrm{norm}}$.\n\nAssuming the compensation model applies at $12$ weeks postoperatively and body surface area normalization remains constant, compute the expected postoperative eGFR after right nephrectomy. Express your answer in $\\mathrm{mL/min/1.73\\,m^2}$ and round your answer to four significant figures. The final value must be a single real number.",
            "solution": "The user wants me to solve the problem by following these steps:\n1.  **Validate the problem:** Check for scientific soundness, completeness, and objectivity.\n2.  **Solve the problem if valid:** Provide a detailed, step-by-step solution.\n3.  **Format the output:** Use XML-style tags, LaTeX for all math, and follow specific formatting rules for the final answer.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n- Baseline estimated Glomerular Filtration Rate (eGFR): $E_{0} = 84 \\,\\mathrm{mL/min/1.73\\,m^2}$.\n- Right kidney fractional contribution to baseline eGFR: $f_{R} = 0.40$.\n- Left kidney fractional contribution to baseline eGFR: $f_{L} = 0.60$.\n- Normal fractional compensation of the contralateral kidney: $c_{\\mathrm{norm}} = 0.30$.\n- Fractional attenuation of compensation due to comorbidities: $a = 0.25$.\n- Surgical procedure: Right nephrectomy.\n- Objective: Compute the expected postoperative eGFR at $12$ weeks.\n- Final Answer Requirement: Round to four significant figures.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded:** The problem is based on established concepts in nephrology and surgical oncology. The model of GFR contribution, unilateral nephrectomy, and subsequent compensatory hyperfiltration is a standard, albeit simplified, framework for clinical prediction. The given values for eGFR, functional split, and compensation are physiologically realistic.\n- **Well-Posed:** The problem provides all necessary data and defines the relationships between variables sufficiently to calculate a unique solution. The sum of fractional contributions is $f_R + f_L = 0.40 + 0.60 = 1.00$, which is consistent.\n- **Objective:** The problem is stated in precise, objective medical and mathematical terminology. It is free from ambiguity and subjective claims.\n- **Conclusion:** The problem does not violate any of the specified invalidity criteria. It is scientifically sound, well-posed, objective, and formalizable.\n\n**Step 3: Verdict and Action**\n- **Verdict:** The problem is **valid**.\n- **Action:** Proceed with the solution.\n\n### Solution\n\nThe objective is to calculate the expected postoperative estimated Glomerular Filtration Rate ($E_{\\text{post}}$) after a right nephrectomy. The calculation will proceed by determining the function of the remaining kidney and modeling its compensatory increase.\n\n1.  **Determine the baseline function of the remaining (left) kidney.**\nThe total baseline eGFR is given as $E_{0} = 84 \\,\\mathrm{mL/min/1.73\\,m^2}$. The left kidney contributes a fraction $f_{L} = 0.60$ to this total. Therefore, the baseline eGFR of the left kidney, denoted as $E_{L}$, is:\n$$E_{L} = E_{0} \\times f_{L}$$\nSubstituting the given values:\n$$E_{L} = 84 \\times 0.60 = 50.4 \\,\\mathrm{mL/min/1.73\\,m^2}$$\n\n2.  **Model the postoperative compensation.**\nAfter the right nephrectomy, the left kidney is the sole source of renal function. It is expected to undergo compensatory hyperfiltration. The model states that this compensation is a fractional increase over its baseline contribution. The normal fractional compensation is $c_{\\mathrm{norm}} = 0.30$. However, this is attenuated by the patient's comorbidities. The fractional attenuation is given as $a = 0.25$. The problem states this attenuation is \"applied multiplicatively to $c_{\\mathrm{norm}}$\". The standard interpretation of a fractional attenuation of $a$ is a reduction by that fraction, which corresponds to multiplication by a factor of $(1-a)$. Therefore, the effective fractional compensation, $c_{\\text{eff}}$, is:\n$$c_{\\text{eff}} = c_{\\mathrm{norm}} \\times (1 - a)$$\nSubstituting the given values:\n$$c_{\\text{eff}} = 0.30 \\times (1 - 0.25) = 0.30 \\times 0.75 = 0.225$$\nThis means the left kidney's function will increase by $22.5\\%$ of its own baseline value.\n\n3.  **Calculate the total postoperative eGFR.**\nThe final postoperative eGFR, $E_{\\text{post}}$, is the baseline function of the left kidney plus the compensatory increase.\n$$E_{\\text{post}} = E_{L} + (\\text{compensatory increase})$$\nThe compensatory increase is the baseline function of the left kidney, $E_{L}$, multiplied by the effective compensation fraction, $c_{\\text{eff}}$.\n$$E_{\\text{post}} = E_{L} + (E_{L} \\times c_{\\text{eff}}) = E_{L} \\times (1 + c_{\\text{eff}})$$\nWe can write a single expression for $E_{\\text{post}}$ in terms of the initial givens:\n$$E_{\\text{post}} = (E_{0} \\times f_{L}) \\times (1 + c_{\\mathrm{norm}}(1 - a))$$\n\n4.  **Compute the final numerical value.**\nUsing the intermediate values calculated above:\n$$E_{\\text{post}} = 50.4 \\times (1 + 0.225)$$\n$$E_{\\text{post}} = 50.4 \\times 1.225$$\n$$E_{\\text{post}} = 61.74 \\,\\mathrm{mL/min/1.73\\,m^2}$$\n\nThe problem requires the answer to be rounded to four significant figures. The calculated value of $61.74$ already has four significant figures.",
            "answer": "$$\\boxed{61.74}$$"
        },
        {
            "introduction": "Intraoperatively, the line between a liposarcoma and normal retroperitoneal fat can be indistinct, creating a significant challenge for margin assessment. Surgeons may be tempted to rely on intraoperative frozen section to guide their resection, but how reliable is this test? This problem challenges you to move beyond intuition and apply formal Bayesian reasoning to quantify the diagnostic utility of a negative frozen section. By calculating the posterior probability of residual disease, you will develop a deeper appreciation for the limitations of this tool and reinforce the fundamental oncologic principle that margin decisions in fatty sarcomas should be driven by preoperative planning and compartmental resection, not by potentially misleading real-time data .",
            "id": "5180333",
            "problem": "A patient aged $64$ years presents with a retroperitoneal mass measuring $28\\ \\mathrm{cm}$, predominantly fatty on preoperative Magnetic Resonance Imaging (MRI), with nodular non-fatty components abutting the left kidney suggestive of dedifferentiation. The multidisciplinary plan is an en bloc resection with consideration of left nephrectomy to achieve a complete gross (macroscopic) resection with negative margins. Intraoperatively, the surgeon contemplates using a frozen section from a $1\\ \\mathrm{cm}$ rim of perinephric fat adjacent to the mass to decide whether the kidney can be spared.\n\nAssume the following scientifically consistent parameters grounded in widely accepted definitions of diagnostic test performance and surgical oncology principles:\n\n- The pretest probability that the sampled margin contains dedifferentiated liposarcoma (DDLPS) is $p_{\\mathrm{DDLPS}}=0.30$.\n- The pretest probability that the sampled margin contains well-differentiated liposarcoma (WDLPS), also termed atypical lipomatous tumor in deep locations, is $p_{\\mathrm{WDLPS}}=0.40$.\n- The pretest probability that the sampled margin is normal retroperitoneal fat without tumor is $p_{\\mathrm{Normal}}=0.30$.\n- For frozen section detection of DDLPS at the margin, the sensitivity is $Se_{\\mathrm{DDLPS}}=0.75$ and the specificity against normal fat is $Sp_{\\mathrm{DDLPS}}=0.95$.\n- For frozen section detection of WDLPS at the margin, the sensitivity is $Se_{\\mathrm{WDLPS}}=0.50$ and the specificity against normal fat is $Sp_{\\mathrm{WDLPS}}=0.85$.\n- Treat the composite call of “any tumor present” on frozen section as the union of either DDLPS or WDLPS detection; the composite specificity against normal for “any tumor” is $Sp_{\\mathrm{Any}}=0.90$.\n\nThe frozen section report returns “no tumor identified” in the sampled $1\\ \\mathrm{cm}$ margin specimen. Using the definitions of sensitivity ($Se$), specificity ($Sp$), and Bayes’ theorem, and integrating core surgical oncology goals for retroperitoneal sarcomas (complete en bloc resection, avoidance of piecemeal excision, and recognition of the multinodular infiltrative nature of WDLPS), choose the single best statement regarding how intraoperative frozen section should be applied judiciously and its limitations for margin decision-making in fatty retroperitoneal sarcomas.\n\nA. Given the stated pretest probabilities and test characteristics, the posterior probability that tumor is present at or beyond the sampled margin remains approximately $0.50$ even after a negative frozen section, so the kidney should not be spared solely on this basis; frozen section is better used to confirm a grossly apparent dedifferentiated focus or unexpected non-sarcoma tissue, while margin decisions in fatty sarcomas should rely on preoperative planning and en bloc compartmental resection principles rather than frozen margins.\n\nB. The negative frozen section lowers the probability of residual tumor at the margin to less than $0.05$, justifying kidney preservation; frozen section can reliably exclude microscopic WDLPS infiltration in retroperitoneal fat.\n\nC. A positive frozen section for WDLPS at the margin mandates nephrectomy, whereas a negative frozen section permits margin shaving; rapid intraoperative Mouse Double Minute 2 homolog (MDM2) amplification testing is available on frozen, ensuring accurate adipocytic tumor classification.\n\nD. Frozen section is unsuitable in fatty sarcomas because adipose tissue cannot be frozen, so it should never be used for any intraoperative decision-making in retroperitoneal liposarcoma.",
            "solution": "The problem statement describing the clinical scenario, the pretest probabilities, and the diagnostic test characteristics for intraoperative frozen section is scientifically grounded, well-posed, and objective. The parameters provided are consistent and sufficient for a rigorous analysis. The total pretest probability is $0.30 + 0.40 + 0.30 = 1.00$. The scenario is a realistic and critical dilemma in surgical oncology. The problem is valid.\n\nThe core of the problem is to calculate the posterior probability that the sampled margin contains tumor, given that the frozen section result is negative. This requires the application of Bayes' theorem.\n\nFirst, let's define the events:\n- $D_{\\mathrm{DDLPS}}$: The margin contains dedifferentiated liposarcoma.\n- $D_{\\mathrm{WDLPS}}$: The margin contains well-differentiated liposarcoma.\n- $D_{\\mathrm{Normal}}$: The margin is normal fat.\n- $D_{\\mathrm{Any}} = D_{\\mathrm{DDLPS}} \\cup D_{\\mathrm{WDLPS}}$: The margin contains any tumor.\n- $T^-$: The frozen section test is negative (\"no tumor identified\").\n\nThe pretest probabilities are given:\n- $P(D_{\\mathrm{DDLPS}}) = 0.30$\n- $P(D_{\\mathrm{WDLPS}}) = 0.40$\n- $P(D_{\\mathrm{Normal}}) = 0.30$\nThe pretest probability of any tumor at the margin is $P(D_{\\mathrm{Any}}) = P(D_{\\mathrm{DDLPS}}) + P(D_{\\mathrm{WDLPS}}) = 0.30 + 0.40 = 0.70$.\n\nThe test characteristics related to a negative result ($T^-$) are:\n- The probability of a negative test given DDLPS (False Negative Rate) is $P(T^-|D_{\\mathrm{DDLPS}}) = 1 - Se_{\\mathrm{DDLPS}} = 1 - 0.75 = 0.25$.\n- The probability of a negative test given WDLPS (False Negative Rate) is $P(T^-|D_{\\mathrm{WDLPS}}) = 1 - Se_{\\mathrm{WDLPS}} = 1 - 0.50 = 0.50$.\n- The probability of a negative test given Normal tissue (True Negative Rate or Specificity) is $P(T^-|D_{\\mathrm{Normal}}) = Sp_{\\mathrm{Any}} = 0.90$.\n\nWe want to find the posterior probability of any tumor being present given a negative test, $P(D_{\\mathrm{Any}} | T^-)$. Using Bayes' theorem:\n$$\nP(D_{\\mathrm{Any}} | T^-) = \\frac{P(T^- | D_{\\mathrm{Any}}) P(D_{\\mathrm{Any}})}{P(T^-)}\n$$\nThe denominator, $P(T^-)$, is the total probability of a negative test, calculated by the law of total probability:\n$$\nP(T^-) = P(T^-|D_{\\mathrm{DDLPS}})P(D_{\\mathrm{DDLPS}}) + P(T^-|D_{\\mathrm{WDLPS}})P(D_{\\mathrm{WDLPS}}) + P(T^-|D_{\\mathrm{Normal}})P(D_{\\mathrm{Normal}})\n$$\nSubstituting the values:\n$$\nP(T^-) = (0.25)(0.30) + (0.50)(0.40) + (0.90)(0.30)\n$$\n$$\nP(T^-) = 0.075 + 0.200 + 0.270 = 0.545\n$$\nThe numerator term, $P(T^- | D_{\\mathrm{Any}}) P(D_{\\mathrm{Any}})$, is equivalent to $P(T^- \\cap D_{\\mathrm{Any}})$. This is the sum of probabilities of a negative test occurring with either type of tumor:\n$$\nP(T^- \\cap D_{\\mathrm{Any}}) = P(T^-|D_{\\mathrm{DDLPS}})P(D_{\\mathrm{DDLPS}}) + P(T^-|D_{\\mathrm{WDLPS}})P(D_{\\mathrm{WDLPS}})\n$$\n$$\nP(T^- \\cap D_{\\mathrm{Any}}) = (0.25)(0.30) + (0.50)(0.40) = 0.075 + 0.200 = 0.275\n$$\nNow, we can calculate the posterior probability:\n$$\nP(D_{\\mathrm{Any}} | T^-) = \\frac{0.275}{0.545} \\approx 0.5045\n$$\nThus, even with a negative frozen section, the probability that the sampled margin contains tumor is approximately $50\\%$.\n\nNow we evaluate each option:\n\nA. Given the stated pretest probabilities and test characteristics, the posterior probability that tumor is present at or beyond the sampled margin remains approximately $0.50$ even after a negative frozen section, so the kidney should not be spared solely on this basis; frozen section is better used to confirm a grossly apparent dedifferentiated focus or unexpected non-sarcoma tissue, while margin decisions in fatty sarcomas should rely on preoperative planning and en bloc compartmental resection principles rather than frozen margins.\n- The calculated posterior probability is indeed approximately $0.50$ (our calculation yielded $\\approx 0.5045$). A $50\\%$ chance of a positive margin is unacceptably high in oncologic surgery, making it unjustifiable to spare the kidney solely on this single piece of unreliable data. This aligns with the core surgical oncology principle of achieving complete resection (R0) for sarcomas to minimize local recurrence. The rest of the statement accurately describes the modern, accepted role of frozen section and the primacy of en bloc resection based on preoperative planning for retroperitoneal sarcomas. The difficulty in diagnosing WDLPS on frozen section and its infiltrative nature makes reliance on negative frozen margins hazardous. This option is consistent with both the mathematical derivation and established clinical principles.\n- **Verdict: Correct.**\n\nB. The negative frozen section lowers the probability of residual tumor at the margin to less than $0.05$, justifying kidney preservation; frozen section can reliably exclude microscopic WDLPS infiltration in retroperitoneal fat.\n- The first part is a quantitatively false statement. Our calculation shows the posterior probability is $\\approx 0.50$, not $<0.05$. The second part is also false; the problem provides a sensitivity of only $0.50$ for WDLPS, which is the definition of un-reliable exclusion.\n- **Verdict: Incorrect.**\n\nC. A positive frozen section for WDLPS at the margin mandates nephrectomy, whereas a negative frozen section permits margin shaving; rapid intraoperative Mouse Double Minute 2 homolog (MDM2) amplification testing is available on frozen, ensuring accurate adipocytic tumor classification.\n- \"Margin shaving\" after a negative frozen section would constitute a piecemeal resection, which is contraindicated in sarcoma surgery, especially when the posterior probability of residual disease is $50\\%$. More importantly, the claim about \"rapid intraoperative\" MDM2 testing is factually incorrect. MDM2 amplification is confirmed by Fluorescence In Situ Hybridization (FISH) or sometimes suggested by immunohistochemistry (IHC). FISH is a lengthy test that takes hours to days and cannot be performed in an intraoperative timeframe.\n- **Verdict: Incorrect.**\n\nD. Frozen section is unsuitable in fatty sarcomas because adipose tissue cannot be frozen, so it should never be used for any intraoperative decision-making in retroperitoneal liposarcoma.\n- The premise that \"adipose tissue cannot be frozen\" is factually wrong. It can be frozen and sectioned, but the process introduces artifacts that make interpretation difficult. The conclusion that it should \"never\" be used is too absolute. As stated in option A, it has specific, appropriate uses, such as confirming a high-grade (dedifferentiated) component or identifying an alternative diagnosis (e.g., lymphoma).\n- **Verdict: Incorrect.**\n\nBased on the rigorous Bayesian analysis and evaluation against established surgical oncology principles, option A is the only statement that is mathematically, clinically, and factually correct.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "A successful oncologic resection marks a transition, not an end, to the patient's care. Long-term surveillance is crucial for detecting recurrence at a treatable stage, but a one-size-fits-all approach is inefficient and can be harmful. This practice focuses on designing a risk-adapted surveillance plan for a patient with a high-grade retroperitoneal sarcoma. You will apply core principles regarding histology-specific recurrence patterns and the declining hazard of recurrence over time to select the appropriate imaging modalities and intervals. This exercise will solidify your ability to create a logical, evidence-based follow-up strategy that balances the benefits of early detection against the burdens of long-term surveillance .",
            "id": "5180345",
            "problem": "A $62$-year-old patient underwent complete (negative margin) resection of a retroperitoneal leiomyosarcoma (LMS) confirmed to be high grade on final pathology. There is no residual disease on immediate postoperative staging. The patient has normal renal function, no contraindication to iodinated contrast, and is otherwise fit for repeated imaging. The multidisciplinary team must design a surveillance plan that is risk-adapted by histology and grade and balances early detection of treatable recurrence with cumulative radiation exposure and cost.\n\nUse the following foundational principles:\n- In retroperitoneal sarcoma (RPS), the time-dependent hazard of recurrence after complete resection is highest in the early postoperative interval, especially for high-grade histologies, and then declines over time. This motivates more frequent imaging early (short-interval surveillance) followed by lengthening intervals as the hazard decreases.\n- Patterns of failure in RPS are histology-specific. Leiomyosarcoma (LMS) has a substantial risk of hematogenous metastasis, particularly to the lungs and liver, in addition to risk of local recurrence. Well-differentiated liposarcoma, by contrast, rarely metastasizes and predominantly recurs locally, often late.\n- Imaging modality choice should align with an organ’s dominant failure mode and with test performance: computed tomography (CT) of the chest is superior to chest radiography for detecting small pulmonary metastases; contrast-enhanced CT or magnetic resonance imaging (MRI) of the abdomen and pelvis are appropriate for local-site surveillance, with CT generally preferred when contrast is safe and readily available. Positron Emission Tomography (PET) is not a routine surveillance tool in asymptomatic RPS due to limited incremental sensitivity for small-volume recurrence and cost.\n\nWhich of the following surveillance strategies is most appropriate for this patient?\n\nA. Annual abdominal and pelvic MRI with gadolinium and annual non-contrast chest radiography for $5$ years, then stop if no recurrence.\n\nB. Contrast-enhanced CT of the chest, abdomen, and pelvis every $3$–$4$ months for the first $2$–$3$ years, then every $6$ months until year $5$, then annually until year $10$.\n\nC. Whole-body PET-CT every $3$ months indefinitely, with no dedicated chest CT.\n\nD. Contrast-enhanced CT of the abdomen and pelvis every $6$ months for the first $2$ years, chest imaging only by radiography annually, then abdominal and pelvic CT annually thereafter with no chest imaging beyond year $3$.\n\nE. Non-contrast CT of the chest, abdomen, and pelvis every $12$ weeks for the first $5$ years, then every $2$ years thereafter indefinitely.",
            "solution": "The problem statement is evaluated for validity prior to attempting a solution.\n\n**Step 1: Extract Givens**\n- Patient: A $62$-year-old.\n- Diagnosis: Retroperitoneal leiomyosarcoma (LMS), high grade.\n- Surgical outcome: Complete resection with negative margins.\n- Postoperative status: No residual disease on staging.\n- Patient fitness: Normal renal function, no contraindication to iodinated contrast, fit for repeated imaging.\n- Surveillance goal: A risk-adapted plan balancing early detection, radiation exposure, and cost.\n- Principle 1 (Recurrence Timing): The hazard of recurrence for high-grade retroperitoneal sarcoma (RPS) is highest in the early postoperative period and declines over time. This justifies more frequent initial surveillance with progressively lengthening intervals.\n- Principle 2 (Recurrence Pattern): Recurrence patterns are histology-specific. Leiomyosarcoma (LMS) has a notable risk of both local recurrence and hematogenous metastasis, especially to the lungs and liver.\n- Principle 3 (Imaging Modality):\n    - For pulmonary metastases, computed tomography (CT) of the chest is superior to chest radiography.\n    - For locoregional surveillance (abdomen and pelvis), contrast-enhanced CT or magnetic resonance imaging (MRI) are appropriate. CT is generally preferred if contrast is permissible.\n    - Positron Emission Tomography (PET) is not a standard routine surveillance tool for asymptomatic RPS.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, presenting a realistic clinical scenario in surgical oncology. The provided principles are consistent with established oncologic guidelines for the management of retroperitoneal sarcomas. The problem is well-posed, providing sufficient information (patient age, diagnosis, tumor grade, surgical result, fitness for imaging) and a clear set of guiding principles to determine the most appropriate course of action from a list of options. The language is objective and precise. The problem contains no scientific inaccuracies, contradictions, or ambiguities.\n\n**Step 3: Verdict and Action**\nThe problem statement is **valid**. A solution will be derived by applying the given principles to the patient's specific case.\n\n**Derivation of the Optimal Surveillance Strategy**\nBased on the provided information and principles, we can construct the ideal surveillance plan for this patient.\n\n1.  **Patient Risk Stratification**: The patient has a high-grade retroperitoneal LMS. The \"high grade\" designation places the patient in a high-risk category for recurrence. The \"LMS\" histology indicates a high propensity for both local recurrence and distant, hematogenous metastases, particularly to the lungs and liver (Principle 2).\n\n2.  **Choice of Imaging Modality**:\n    -   **Local and Hepatic Surveillance (Abdomen/Pelvis)**: Given the risk of local recurrence and liver metastases, high-quality cross-sectional imaging of the abdomen and pelvis is required. The patient has normal renal function and no contraindications to iodinated contrast. Therefore, according to Principle 3, contrast-enhanced CT is the preferred modality.\n    -   **Pulmonary Surveillance (Chest)**: Given the substantial risk of lung metastases for LMS, effective chest surveillance is critical. Principle 3 explicitly states that CT of the chest is superior to chest radiography for detecting small pulmonary nodules. Therefore, chest CT is the required modality.\n    -   **Combined Modality**: The most efficient and comprehensive approach is a contrast-enhanced CT of the chest, abdomen, and pelvis.\n    -   **Role of PET**: Principle 3 rules out routine PET-CT as a primary surveillance tool.\n\n3.  **Frequency and Duration of Surveillance**:\n    -   Principle 1 dictates that for high-grade tumors, the surveillance frequency should be highest initially and decrease over time. The highest risk of recurrence is within the first $2$ to $3$ years post-resection.\n    -   Therefore, an appropriate schedule would involve imaging at short intervals (e.g., every $3$ to $6$ months) for the first $2$ to $3$ years.\n    -   As the time from surgery increases and the hazard rate declines, the interval can be lengthened (e.g., to every $6$ months, then annually).\n    -   Surveillance is typically continued for an extended period, such as $10$ years, as late recurrences, while less common, can still occur.\n\n**Summary of the Ideal Plan**: The optimal strategy involves contrast-enhanced CT of the chest, abdomen, and pelvis, performed every $3$–$6$ months for the first $2$–$3$ years, followed by a gradual tapering of frequency to every $6$ months and then annually, for a total duration of up to $10$ years.\n\n**Evaluation of Options**\n\n**A. Annual abdominal and pelvic MRI with gadolinium and annual non-contrast chest radiography for $5$ years, then stop if no recurrence.**\n-   **Analysis**: This option employs chest radiography, which is explicitly noted as an inferior modality for detecting pulmonary metastases (violates Principle 3). Furthermore, the surveillance frequency is only annual from the start, which is insufficient for a high-risk, high-grade sarcoma in the early, highest-risk period (violates Principle 1). Stopping all surveillance at $5$ years is also questionable for a high-grade tumor.\n-   **Verdict**: Incorrect.\n\n**B. Contrast-enhanced CT of the chest, abdomen, and pelvis every $3$–$4$ months for the first $2$–$3$ years, then every $6$ months until year $5$, then annually until year $10$.**\n-   **Analysis**: This strategy aligns perfectly with the derived ideal plan.\n    -   **Modality**: It uses contrast-enhanced CT of the chest, abdomen, and pelvis, which is the optimal choice based on Principles 2 and 3 and the patient's clinical status.\n    -   **Frequency and Duration**: The schedule—frequent imaging every $3$–$4$ months during the highest-risk period ($2$–$3$ years), followed by tapering to every $6$ months and then annually up to year $10$—is a direct and correct application of Principle 1.\n-   **Verdict**: Correct.\n\n**C. Whole-body PET-CT every $3$ months indefinitely, with no dedicated chest CT.**\n-   **Analysis**: This option relies on PET-CT as the primary surveillance tool. Principle 3 explicitly states that PET is not a routine surveillance tool for this purpose. The schedule of \"every $3$ months indefinitely\" also fails to incorporate the concept of lengthening intervals as the hazard of recurrence declines over time (violates Principles 1 and 3).\n-   **Verdict**: Incorrect.\n\n**D. Contrast-enhanced CT of the abdomen and pelvis every $6$ months for the first $2$ years, chest imaging only by radiography annually, then abdominal and pelvic CT annually thereafter with no chest imaging beyond year $3$.**\n-   **Analysis**: This option has several critical flaws. It uses suboptimal chest radiography instead of CT (violates Principle 3). It only performs chest imaging annually, which is too infrequent. Most severely, it ceases all chest surveillance after year $3$, completely ignoring the ongoing risk of pulmonary metastases, which is a primary failure pattern for LMS (violates Principle 2).\n-   **Verdict**: Incorrect.\n\n**E. Non-contrast CT of the chest, abdomen, and pelvis every $12$ weeks for the first $5$ years, then every $2$ years thereafter indefinitely.**\n-   **Analysis**: This option proposes non-contrast CT. Since the patient has no contraindication to contrast, this is a suboptimal choice, particularly for assessing local recurrence and liver metastases where contrast enhancement is critical for characterization (violates the preference stated in Principle 3). Additionally, maintaining a high-frequency interval of every $12$ weeks for a full $5$ years, without tapering, is not consistent with the principle of adapting to the declining hazard rate over time (violates Principle 1). This would lead to excessive radiation exposure without clear benefit over a tapered schedule.\n-   **Verdict**: Incorrect.",
            "answer": "$$\\boxed{B}$$"
        }
    ]
}